---
title: "Paxlovid (nirmatrelvir; ritonavir) in COVID-19: Clinical trials questions"
description: "Clinical trials questions on Paxlovid (nirmatrelvir; ritonavir) in COVID-19, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Study results, Subgroup results, and Interpreting study results. Questions: How much did Paxlovid lower viral load vs placebo by Day 5 (EPIC-HR, EPIC-SR)? How was the Paxlovid EPIC-HR trial designed? How well does Paxlovid prevent COVID-19 hospitalization or death vs placebo (EPIC-HR)? Did fewer people die on Paxlovid than placebo in EPIC-HR? 6 further questions follow. 10 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/paxlovid--covid-19/clinical-trials"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Paxlovid (nirmatrelvir; ritonavir) in COVID-19: Clinical trials questions

Manufacturer: Pfizer Inc  
Prescribing information: [Paxlovid](https://labeling.pfizer.com/ShowLabeling.aspx?id=19599)

Clinical trials questions that apply to every indication of Paxlovid are on [Paxlovid (nirmatrelvir; ritonavir), all indications: Clinical trials](https://www.evicenter.com/medical-information/paxlovid/clinical-trials).

## Study results

<a id="paxlovid-viral-load"></a>

### How much did Paxlovid lower viral load vs placebo by Day 5 (EPIC-HR, EPIC-SR)?

> “In clinical trial EPIC-HR, which enrolled subjects who were primarily infected with the SARS-CoV-2 Delta variant, PAXLOVID treatment was associated with a 0.83 log10 copies/mL greater median decline in viral RNA shedding levels in nasopharyngeal samples through Day 5 (mITT1 analysis set, all treated subjects with onset of symptoms ≤5 days who at baseline did not receive nor were expected to receive COVID-19 therapeutic mAb treatment); similar results were observed in the mITT2 analysis set (all treated subjects with onset of symptoms ≤5 days). In the EPIC-SR trial, which included subjects who were infected with SARS-CoV-2 Delta (79%) or Omicron (19%) variants, PAXLOVID treatment was associated with a 1.05 log10 copies/mL greater median decline in viral RNA shedding levels in nasopharyngeal samples through Day 5, with similar declines observed in subjects infected with Delta or Omicron variants. The degree of reduction in viral RNA levels relative to placebo following 5 days of PAXLOVID treatment was similar between unvaccinated high-risk subjects in EPIC-HR and vaccinated high-risk subjects in EPIC-SR.”

Source: [PAXLOVID: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19599#:~:text=In%20clinical%20trial%20EPIC%2DHR%2C%20which,vaccinated%20high%2Drisk%20subjects%20in%20EPIC%2DSR.)

Note: The EPIC-SR value is for all EPIC-SR participants, who included unvaccinated adults without risk factors, a population for which Paxlovid is not indicated.

<a id="paxlovid-epic-hr-hospitalization-death"></a>

### How well does Paxlovid prevent COVID-19 hospitalization or death vs placebo (EPIC-HR)?

> “Table 9 provides results of the primary endpoint in mITT1 analysis population. For the primary endpoint, the relative risk reduction in the mITT1 analysis population for PAXLOVID compared to placebo was 86% (95% CI: 72%, 93%).”

Source: [PAXLOVID: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19599#:~:text=Table%209%20provides%20results%20of,86%25%20%2895%25%20CI%3A%2072%25%2C%2093%25%29.)

> “Table 9: COVID-19 Related Hospitalization or Death from Any Cause Through Day 28 in Non-Hospitalized Adults with COVID-19 (mITT1 Analysis Set): EPIC-HR
> 	PAXLOVID
> (N=977)	Placebo
> (N=989)
> Abbreviations: CI=confidence interval; COVID-19=coronavirus disease 2019; mAb=monoclonal antibody; mITT1=modified intent-to-treat 1 (all treated subjects with onset of symptoms ≤5 days who at baseline did not receive nor were expected to receive COVID-19 therapeutic mAb treatment).
> The determination of primary efficacy was based on a planned interim analysis of 754 subjects in mITT population. The estimated risk reduction was -6.5% with a 95% CI of (-9.3%, -3.7%) and 2-sided p-value <0.0001.
>
> *
> The estimated cumulative proportion of subjects hospitalized or death by Day 28 was calculated for each treatment group using the Kaplan-Meier method, where subjects without hospitalization and death status through Day 28 were censored at the time of study discontinuation.
> †
> For the secondary endpoint of all-cause mortality through Week 24, there were 0 and 15 (1%) events in the PAXLOVID arm and placebo arm, respectively.
>
>
>
> COVID-19 Related Hospitalization or Death from Any Cause Through Day 28
>
>
>
>
> n (%)
>
>
>
> 9 (0.9%)
>
>
>
> 64 (6.5%)
>
>
>
>
> Reduction Relative to Placebo* (95% CI), %
>
>
>
> -5.6 (-7.3, -4.0)
>
>
>
>
> COVID-19 Related Hospitalization Through Day 28, %
>
>
>
> 9 (0.9%)
>
>
>
> 63 (6.4%)
>
>
>
>
> All-cause Mortality Through Day 28†, %
>
>
>
> 0
>
>
>
> 12 (1.2%)”

Source: [PAXLOVID: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19599#:~:text=Table%209%3A%20COVID%2D19%20Related%20Hospitalization,12%20%281.2%25%29)

> “5.6% absolute risk reduction in hospitalization or death (95% Cl, -7.3 to -4.0; P<0.0001)”

Source: [PAXLOVID: Trial Results, captured 2026-11-13](https://paxlovid.pfizerpro.com/efficacy-design/efficacy#:~:text=5.6%25%20absolute%20risk%20reduction%20in,Cl%2C%20%2D7.3%20to%20%2D4.0%3B%20P%3C0.0001%29)

> “The trial excluded individuals with a history of prior COVID-19 infection or vaccination and excluded individuals taking any medications with clinically significant drug interactions with PAXLOVID.”

Source: [PAXLOVID: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19599#:~:text=The%20trial%20excluded%20individuals%20with,significant%20drug%20interactions%20with%20PAXLOVID.)

Note: Table 9 columns are PAXLOVID (N=977) followed by placebo (N=989).

<a id="paxlovid-epic-hr-death"></a>

### Did fewer people die on Paxlovid than placebo in EPIC-HR?

> “All-cause Mortality Through Day 28†, %
>
>
>
> 0
>
>
>
> 12 (1.2%)”

Source: [PAXLOVID: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19599#:~:text=All%2Dcause%20Mortality%20Through%20Day%2028%E2%80%A0%2C,12%20%281.2%25%29)

> “†
> For the secondary endpoint of all-cause mortality through Week 24, there were 0 and 15 (1%) events in the PAXLOVID arm and placebo arm, respectively.”

Source: [PAXLOVID: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19599#:~:text=For%20the%20secondary%20endpoint%20of,arm%20and%20placebo%20arm%2C%20respectively.)

Note: The first value is PAXLOVID (N=977) and the second placebo (N=989), from Table 9 of the Prescribing Information (EPIC-HR, mITT1 analysis set).

<a id="paxlovid-epic-hr-within-3-days"></a>

### How effective was Paxlovid when started within 3 days of symptoms (EPIC-HR)?

> “For patients treated within 3 days of symptom onset (mITT)
>
> 89% relative risk reduction in hospitalization or death<sup>†</sup>
>
> PAXLOVID event rate: 5/671 (0.7%) vs placebo event rate: 44/647 (6.8%)
> -6.1% difference compared with placebo (95% Cl, -8.2 to -4.1; P<0.0001)”

Source: [PAXLOVID: Trial Results, captured 2026-11-13](https://paxlovid.pfizerpro.com/efficacy-design/efficacy#:~:text=For%20patients%20treated%20within%203,Cl%2C%20%2D8.2%20to%20%2D4.1%3B%20P%3C0.0001%29)

> “†mITT analysis set=all treated participants with onset of symptoms within 3 days who at baseline did not receive nor were expected to receive COVID-19 therapeutic mAb treatment.”

Source: [PAXLOVID: Trial Results, captured 2026-11-13](https://paxlovid.pfizerpro.com/efficacy-design/efficacy#:~:text=%E2%80%A0mITT%20analysis%20set%3Dall%20treated%20participants,receive%20COVID%2D19%20therapeutic%20mAb%20treatment.)

Note: Results are COVID-19-related hospitalization or death from any cause through Day 28 compared with placebo.

<a id="paxlovid-epic-sr-vaccinated"></a>

### What were the results of the Paxlovid EPIC-SR trial?

> “EPIC-SR (NCT05011513) was a Phase 2/3, randomized, double-blind, placebo-controlled trial in non-hospitalized symptomatic adult subjects with a laboratory confirmed diagnosis of SARS-CoV-2 infection. Eligible subjects were 18 years of age or older with COVID-19 symptom onset of ≤5 days who were at standard risk for progression to severe disease. The trial included previously unvaccinated subjects with no risk factors for progression to severe disease or subjects fully vaccinated against COVID-19 (i.e., completed a primary vaccination series) with at least 1 of the risk factors for progression to severe disease as defined in EPIC-HR. Through the December 19, 2021, data cutoff, a total of 1,075 subjects were randomized (1:1) to receive PAXLOVID or placebo orally every 12 hours for 5 days; of these, 59% were fully vaccinated high-risk subjects.
>
> The primary endpoint in this trial, the difference in time to sustained alleviation of all targeted COVID-19 signs and symptoms through Day 28 among PAXLOVID versus placebo recipients, was not met.
>
> In an exploratory analysis of the subgroup of fully vaccinated subjects with at least 1 risk factor for progression to severe disease, a non-statistically significant numerical reduction relative to placebo for the secondary endpoint of COVID-19 related hospitalization or death from any cause through Day 28 was observed.”

Source: [PAXLOVID: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19599#:~:text=EPIC%2DSR%20%28NCT05011513%29%20was%20a%20Phase,through%20Day%2028%20was%20observed.)

Note: EPIC-SR also enrolled unvaccinated adults without risk factors, a population for which Paxlovid is not indicated. The hospitalization or death result in vaccinated high-risk participants was an exploratory analysis.

## Clinical trials

<a id="paxlovid-epic-hr-design"></a>

### How was the Paxlovid EPIC-HR trial designed?

> “EPIC-HR (NCT04960202) was a Phase 2/3, randomized, double-blind, placebo-controlled trial in non-hospitalized symptomatic adult subjects with a laboratory confirmed diagnosis of SARS-CoV-2 infection. Eligible subjects were 18 years of age and older with at least 1 of the following risk factors for progression to severe disease: diabetes, overweight (BMI >25), chronic lung disease (including asthma), chronic kidney disease, current smoker, immunosuppressive disease or immunosuppressive treatment, cardiovascular disease, hypertension, sickle cell disease, neurodevelopmental disorders, active cancer, medically-related technological dependence, or were 60 years of age and older regardless of comorbidities. Subjects with COVID-19 symptom onset of ≤5 days were included in the study. Subjects were randomized (1:1) to receive PAXLOVID (nirmatrelvir/ritonavir 300 mg/100 mg) or placebo orally every 12 hours for 5 days. The trial excluded individuals with a history of prior COVID-19 infection or vaccination and excluded individuals taking any medications with clinically significant drug interactions with PAXLOVID. The primary efficacy endpoint was the proportion of subjects with COVID-19 related hospitalization or death from any cause through Day 28. The analysis was conducted in the modified intent-to-treat (mITT) analysis set [all treated subjects with onset of symptoms ≤3 days who at baseline did not receive nor were expected to receive COVID-19 therapeutic monoclonal antibody (mAb) treatment], the mITT1 analysis set (all treated subjects with onset of symptoms ≤5 days who at baseline did not receive nor were expected to receive COVID-19 therapeutic mAb treatment), and the mITT2 analysis set (all treated subjects with onset of symptoms ≤5 days).”

Source: [PAXLOVID: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19599#:~:text=EPIC%2DHR%20%28NCT04960202%29%20was%20a%20Phase,onset%20of%20symptoms%20%E2%89%A45%20days%29.)

<a id="paxlovid-epic-hr-risk-factors"></a>

### What were the most common risk factors in Paxlovid EPIC-HR patients?

> “At baseline, the most common underlying medical conditions and factors associated with high risk of progression to severe COVID-19 included in EPIC-HR were:
> BMI ≥25 kg/m<sup>2</sup>: 80.1%
> Cigarette smoker: 39.1%
> Hypertension: 31.8%
> Diabetes mellitus: 10.8%”

Source: [PAXLOVID: Trial Design, captured 2026-11-13](https://paxlovid.pfizerpro.com/efficacy-design/trial-design#:~:text=At%20baseline%2C%20the%20most%20common,Diabetes%20mellitus%3A%2010.8%25)

> “1263 participants (59.8%) had 2 or more such characteristics or coexisting conditions”

Source: [PAXLOVID: Trial Design, captured 2026-11-13](https://paxlovid.pfizerpro.com/efficacy-design/trial-design#:~:text=1263%20participants%20%2859.8%25%29%20had%202%20or%20more%20such%20characteristics%20or%20coexisting%20conditions)

## Subgroup results

<a id="paxlovid-epic-hr-by-age"></a>

### How effective was Paxlovid by age group in EPIC-HR?

> “Participants ≤60 years of age
> saw a 78% relative risk reduction in hospitalization or death
> PAXLOVID event rate: 8/804 (1.0%) vs placebo event rate: 36/783 (4.6%)
> -3.66% difference relative to placebo [95% CI, -5.31 to -2.02]
> Participants ≤60 years of age comprised 80.7% of the mITT1 analysis set (n=1587)
> Participants >60 years of age
> saw a 96% relative risk reduction in hospitalization or death
> PAXLOVID event rate: 1/173 (0.6%) vs placebo event rate: 28/206 (13.6%)
> -13.13% difference relative to placebo [95% CI, -17.98 to -8.28]
> Participants >60 years of age comprised 19.3% of the mITT1 analysis set (n=379)”

Source: [PAXLOVID: Trial Results, captured 2026-11-13](https://paxlovid.pfizerpro.com/efficacy-design/efficacy#:~:text=Participants%20%E2%89%A460%20years%20of%20age,the%20mITT1%20analysis%20set%20%28n%3D379%29)

> “Similar trends have been observed across subgroups of subjects (see Figure 1).”

Source: [PAXLOVID: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19599#:~:text=Similar%20trends%20have%20been%20observed%20across%20subgroups%20of%20subjects%20%28see%20Figure%201%29.)

Note: Results are COVID-19-related hospitalization or death from any cause through Day 28 compared with placebo in the mITT1 analysis set.

<a id="paxlovid-epic-hr-seropositive"></a>

### Did Paxlovid work in EPIC-HR patients with prior SARS-CoV-2 antibodies?

> “Among subjects who were SARS-CoV-2 seropositive at baseline, 1/490 (0.2%) PAXLOVID recipients versus 8/479 (1.7%) placebo recipients met the primary endpoint of COVID-19 related hospitalization or death from any cause through Day 28 [reduction relative to placebo -1.47% (-2.70%, -0.25%)].”

Source: [PAXLOVID: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19599#:~:text=Among%20subjects%20who%20were%20SARS%2DCoV%2D2,to%20placebo%20%2D1.47%25%20%28%2D2.70%25%2C%20%2D0.25%25%29%5D.)

## Interpreting study results

<a id="paxlovid-epic-hr-limitations"></a>

### What are the limitations of the Paxlovid EPIC-HR trial?

> “Trial limitations
> PAXLOVID was approved based primarily on the EPIC-HR trial, a single, randomized, clinical trial that has not been replicated<sup>1,6</sup>
> No vaccinated patients were included in the trial; however, 49.1% of participants were SARS-CoV-2 seropositive at baseline
> The CDC high-risk criteria differ in some aspects from the EPIC-HR trial risk factor inclusion criteria<sup>1,5</sup>”

Source: [PAXLOVID: Trial Design, captured 2026-11-13](https://paxlovid.pfizerpro.com/efficacy-design/trial-design#:~:text=Trial%20limitations,EPIC%2DHR%20trial%20risk%20factor%20inclusion)

> “EPIC-HR was initiated on July 16, 2021, during early vaccination efforts; therefore, PAXLOVID was studied in the absence of vaccine-induced immunity.”

Source: [PAXLOVID: Trial Design, captured 2026-11-13](https://paxlovid.pfizerpro.com/efficacy-design/trial-design#:~:text=EPIC%2DHR%20was%20initiated%20on%20July,the%20absence%20of%20vaccine%2Dinduced%20immunity.)

## Related pages
- [Medical information: Paxlovid (nirmatrelvir; ritonavir): COVID-19](https://www.evicenter.com/medical-information/paxlovid--covid-19)
- [Indication](https://www.evicenter.com/medical-information/paxlovid--covid-19/indication)
- [Real-world evidence](https://www.evicenter.com/medical-information/paxlovid--covid-19/real-world-evidence)
- [Safety](https://www.evicenter.com/medical-information/paxlovid--covid-19/safety)
- [Specific populations](https://www.evicenter.com/medical-information/paxlovid--covid-19/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/paxlovid--covid-19/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/paxlovid--covid-19/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/paxlovid--covid-19/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/paxlovid--covid-19/guidelines)
